Dana Farber Cancer Institute

Site:	Dana Farber Cancer Institute			Go to their website
Address:	450 Brookline Ave
City:	Boston
State:	MA
Zip:	02215-5450
Country:	USA

70 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [asc]	NCT#
2	SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas	Completed	Closed	SU5416	NCT00005862
3	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumors (Gist)	Completed	Closed	Sunitinib	NCT00075218
2	A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor	Completed	Closed	Sunitinib	NCT01396148
1	A Non-randomized, Open-label, Single-center Phase Ib Study of Short Cycles of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors: SURE Trial	Ongoing, but not recruiting	Closed	Sunitinib + Regorafenib	NCT02164240
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Active, not recruiting	Not yet activated	Temozolomide	NCT03556384
1/2	A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Active, not recruiting	Closed	THE-630	NCT05160168
1	Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors	Ongoing, but not recruiting	Closed	XL147	NCT00486135
2	A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib	Completed	Closed	XL820	NCT00570635
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915
1	A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Recruiting	Active	Ziftomenib + Imatinib	NCT06655246